| Dr Mark Robert Anderson, MD, MSC | |
|
500 Martha Jefferson Dr, Charlottesville, VA 22911-4668 | |
| (434) 654-5260 | |
| (844) 340-9731 |
| Full Name | Dr Mark Robert Anderson |
|---|---|
| Gender | Male |
| Speciality | Urology |
| Experience | 16 Years |
| Location | 500 Martha Jefferson Dr, Charlottesville, Virginia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1922156181 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208800000X | Urology | 2011-00424 (North Carolina) | Secondary |
| 208800000X | Urology | 0101267017 (Virginia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Sentara Martha Jefferson Hospital | Charlottesville, VA | Hospital |
| Lewisgale Medical Center | Salem, VA | Hospital |
| Novant Health Uva Health System Culpeper Med Cente | Culpeper, VA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Martha Jefferson Medical Group Llc | 5991889081 | 181 |
| Lewis Gale Physicians Llc | 6507886231 | 211 |
News Archive
The Movember Foundation, the Ontario Institute for Cancer Research and Prostate Cancer Canada today announced $3 million in funding for a new Phase III clinical trial to evaluate if magnetic resonance imaging (MRI) can replace the current standard of care to diagnose prostate cancer.
MultiCell Technologies, Inc. and its majority owned subsidiary, Xenogenics Corporation, are pleased to announce the acquisition of the Ideal™ BioStent assets by Xenogenics Corporation from investment funds managed by Western Technology Investment and Silicon Valley Bank. Xenogenics Corporation also entered into a worldwide exclusive license with Rutgers University for rights to certain intellectual property related to the Ideal™ BioStent.
Survival of adult patients with low-grade gliomas is better if they are admitted to a hospital that favors early resection, rather than one that opts for biopsy and watchful waiting, shows a study in JAMA.
"The number two Senate Republican said Tuesday replacing a public health care option with a nonprofit private cooperative wouldn't win any more Republican support, saying they are essentially the same thing," The Wall Street Journal reports. "Sen. Jon Kyl (R., Ariz.), said Republican objections were more fundamental than simply changing the name of a new national entity to compete with private medical insurers."
› Verified 8 days ago
| Entity Name | University Of Virginia Physicians Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033138250 PECOS PAC ID: 4880590728 Enrollment ID: O20040102000780 |
News Archive
The Movember Foundation, the Ontario Institute for Cancer Research and Prostate Cancer Canada today announced $3 million in funding for a new Phase III clinical trial to evaluate if magnetic resonance imaging (MRI) can replace the current standard of care to diagnose prostate cancer.
MultiCell Technologies, Inc. and its majority owned subsidiary, Xenogenics Corporation, are pleased to announce the acquisition of the Ideal™ BioStent assets by Xenogenics Corporation from investment funds managed by Western Technology Investment and Silicon Valley Bank. Xenogenics Corporation also entered into a worldwide exclusive license with Rutgers University for rights to certain intellectual property related to the Ideal™ BioStent.
Survival of adult patients with low-grade gliomas is better if they are admitted to a hospital that favors early resection, rather than one that opts for biopsy and watchful waiting, shows a study in JAMA.
"The number two Senate Republican said Tuesday replacing a public health care option with a nonprofit private cooperative wouldn't win any more Republican support, saying they are essentially the same thing," The Wall Street Journal reports. "Sen. Jon Kyl (R., Ariz.), said Republican objections were more fundamental than simply changing the name of a new national entity to compete with private medical insurers."
› Verified 8 days ago
| Entity Name | Lewis Gale Physicians Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1902977705 PECOS PAC ID: 6507886231 Enrollment ID: O20051128000164 |
News Archive
The Movember Foundation, the Ontario Institute for Cancer Research and Prostate Cancer Canada today announced $3 million in funding for a new Phase III clinical trial to evaluate if magnetic resonance imaging (MRI) can replace the current standard of care to diagnose prostate cancer.
MultiCell Technologies, Inc. and its majority owned subsidiary, Xenogenics Corporation, are pleased to announce the acquisition of the Ideal™ BioStent assets by Xenogenics Corporation from investment funds managed by Western Technology Investment and Silicon Valley Bank. Xenogenics Corporation also entered into a worldwide exclusive license with Rutgers University for rights to certain intellectual property related to the Ideal™ BioStent.
Survival of adult patients with low-grade gliomas is better if they are admitted to a hospital that favors early resection, rather than one that opts for biopsy and watchful waiting, shows a study in JAMA.
"The number two Senate Republican said Tuesday replacing a public health care option with a nonprofit private cooperative wouldn't win any more Republican support, saying they are essentially the same thing," The Wall Street Journal reports. "Sen. Jon Kyl (R., Ariz.), said Republican objections were more fundamental than simply changing the name of a new national entity to compete with private medical insurers."
› Verified 8 days ago
| Entity Name | Martha Jefferson Medical Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1275720559 PECOS PAC ID: 5991889081 Enrollment ID: O20080228000055 |
News Archive
The Movember Foundation, the Ontario Institute for Cancer Research and Prostate Cancer Canada today announced $3 million in funding for a new Phase III clinical trial to evaluate if magnetic resonance imaging (MRI) can replace the current standard of care to diagnose prostate cancer.
MultiCell Technologies, Inc. and its majority owned subsidiary, Xenogenics Corporation, are pleased to announce the acquisition of the Ideal™ BioStent assets by Xenogenics Corporation from investment funds managed by Western Technology Investment and Silicon Valley Bank. Xenogenics Corporation also entered into a worldwide exclusive license with Rutgers University for rights to certain intellectual property related to the Ideal™ BioStent.
Survival of adult patients with low-grade gliomas is better if they are admitted to a hospital that favors early resection, rather than one that opts for biopsy and watchful waiting, shows a study in JAMA.
"The number two Senate Republican said Tuesday replacing a public health care option with a nonprofit private cooperative wouldn't win any more Republican support, saying they are essentially the same thing," The Wall Street Journal reports. "Sen. Jon Kyl (R., Ariz.), said Republican objections were more fundamental than simply changing the name of a new national entity to compete with private medical insurers."
› Verified 8 days ago
| Entity Name | Blue Ridge Urological Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1528394228 PECOS PAC ID: 3779622196 Enrollment ID: O20091124000706 |
News Archive
The Movember Foundation, the Ontario Institute for Cancer Research and Prostate Cancer Canada today announced $3 million in funding for a new Phase III clinical trial to evaluate if magnetic resonance imaging (MRI) can replace the current standard of care to diagnose prostate cancer.
MultiCell Technologies, Inc. and its majority owned subsidiary, Xenogenics Corporation, are pleased to announce the acquisition of the Ideal™ BioStent assets by Xenogenics Corporation from investment funds managed by Western Technology Investment and Silicon Valley Bank. Xenogenics Corporation also entered into a worldwide exclusive license with Rutgers University for rights to certain intellectual property related to the Ideal™ BioStent.
Survival of adult patients with low-grade gliomas is better if they are admitted to a hospital that favors early resection, rather than one that opts for biopsy and watchful waiting, shows a study in JAMA.
"The number two Senate Republican said Tuesday replacing a public health care option with a nonprofit private cooperative wouldn't win any more Republican support, saying they are essentially the same thing," The Wall Street Journal reports. "Sen. Jon Kyl (R., Ariz.), said Republican objections were more fundamental than simply changing the name of a new national entity to compete with private medical insurers."
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Mark Robert Anderson, MD, MSC Po Box 9007, Charlottesville, VA 22906-9007 Ph: () - | Dr Mark Robert Anderson, MD, MSC 500 Martha Jefferson Dr, Charlottesville, VA 22911-4668 Ph: (434) 654-5260 |
News Archive
The Movember Foundation, the Ontario Institute for Cancer Research and Prostate Cancer Canada today announced $3 million in funding for a new Phase III clinical trial to evaluate if magnetic resonance imaging (MRI) can replace the current standard of care to diagnose prostate cancer.
MultiCell Technologies, Inc. and its majority owned subsidiary, Xenogenics Corporation, are pleased to announce the acquisition of the Ideal™ BioStent assets by Xenogenics Corporation from investment funds managed by Western Technology Investment and Silicon Valley Bank. Xenogenics Corporation also entered into a worldwide exclusive license with Rutgers University for rights to certain intellectual property related to the Ideal™ BioStent.
Survival of adult patients with low-grade gliomas is better if they are admitted to a hospital that favors early resection, rather than one that opts for biopsy and watchful waiting, shows a study in JAMA.
"The number two Senate Republican said Tuesday replacing a public health care option with a nonprofit private cooperative wouldn't win any more Republican support, saying they are essentially the same thing," The Wall Street Journal reports. "Sen. Jon Kyl (R., Ariz.), said Republican objections were more fundamental than simply changing the name of a new national entity to compete with private medical insurers."
› Verified 8 days ago
Dr. Kirsten Greene, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 500 Ray C Hunt Dr, Charlottesville, VA 22903 Phone: 434-924-2224 Fax: 434-244-9481 | |
Mikel Gray, N.P. Urology Medicare: Accepting Medicare Assignments Practice Location: 500 Ray C Hunt Dr Fl 3, Charlottesville, VA 22903 Phone: 434-924-2224 Fax: 434-982-3652 | |
Jacqueline Marie Zillioux, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 500 Ray C Hunt Dr, Charlottesville, VA 22903 Phone: 434-924-2224 Fax: 434-244-9481 | |
Ryan P. Smith, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 500 Ray C Hunt Dr, Charlottesville, VA 22903 Phone: 434-924-2224 Fax: 434-982-3652 | |
Stephen H. Culp, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 500 Ray C Hunt Dr, Charlottesville, VA 22903 Phone: 434-924-2224 Fax: 434-244-9481 | |
Adel B. Guirguis, M.D. Urology Medicare: Not Enrolled in Medicare Practice Location: Uva Hospital W, Hospital Drive, Charlottesville, VA 22908 Phone: 434-924-2224 Fax: 434-243-6878 | |
Dr. Frazier T Fortenberry Jr., MD Urology Medicare: Accepting Medicare Assignments Practice Location: 630 Peter Jefferson Pkwy, Suite 135, Charlottesville, VA 22911 Phone: 434-244-5722 Fax: 434-244-5723 |